Radulović Sinisa, Branković-Magić Mirjana, Janković Radmila, Ristanović Momcilo
Institute for Oncology and Radiology of Serbia, Belgrade.
Srp Arh Celok Lek. 2003 Jul-Aug;131(7-8):345-50.
Germline mutations in BRCA 1 and BRCA 2 gene have been recognized as hereditary predisposition for breast and ovarian cancer for many years. The optimal clinical management of individuals at risk for hereditary breast and ovarian cancer are not completely defined. Current surveillance options are restricted in their effectiveness as well as limitations of the techniques. Surgical prevention interventions are effective, but may be complicated by physical and psychological morbidity. Genetic testing, which plays a role in defining risk, requires careful pre- and post-test counseling to discuss the limitations of testing itself and available management strategies.
多年来，BRCA 1和BRCA 2基因的种系突变已被认为是乳腺癌和卵巢癌的遗传易感性因素。遗传性乳腺癌和卵巢癌高危个体的最佳临床管理尚未完全明确。目前的监测方法在有效性以及技术局限性方面都受到限制。手术预防干预措施是有效的，但可能会因身体和心理疾病而变得复杂。在确定风险方面发挥作用的基因检测需要在检测前和检测后进行仔细的咨询，以讨论检测本身的局限性和可用的管理策略。
